Please assess the completion status of the following clinical trial:

Trial Title: 13 Valent Pneumococcal Conjugate Vaccine - Follow-on Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant completed the Wyeth-sponsored PCV13 infant trial study (6096A1-007) at one of the study sites participating in this follow-on study.~2. Aged 39-46 months (inclusive) at time of enrolment.~3. Available for entire study period and whose parent/legal guardian can be reached by telephone.~4. Healthy children as determined by medical history, physical examination, done by a study nurse (and/or study doctor if required, depending on the medical history of the participant and physical assessment), and judgment of the investigator.~5. Parent/legal guardian must be able to complete all relevant study procedures during study participation.~Exclusion Criteria:~1. Has received further doses of pneumococcal vaccination with licensed or investigational pneumococcal vaccine other than those given as part of the Wyeth-sponsored PCV13 infant trial study (6096A1-007).~2. A previous anaphylactic reaction to any vaccine or vaccine-related component.~3. Contraindication to vaccination with pneumococcal conjugate vaccine.~4. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.~5. Known or suspected immune deficiency or suppression.~6. History of culture-proven invasive disease caused by S pneumoniae.~7. Major known congenital malformation or serious chronic disorder.~8. Significant neurologic disorder or history of seizures including febrile seizure, or significant stable or evolving disorders such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorder.~9. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, synagisB).~10. Participation in another investigational study other than the Wyeth-sponsored PCV13 infant trial study (6096A1-007). Participation in purely observational studies is acceptable.~11. Child who is a direct descendant (child, grandchild) of the study site personnel.

- Gender: ALL
- Minimum Age: 39 Months
- Maximum Age: 46 Months
- Healthy Volunteers: t

Study Arms:
- PCV13 (Type: EXPERIMENTAL): Initial vaccination with PCV13
- PCV7 (Type: EXPERIMENTAL): Initial intervention with PCV7

Based on this trial design, predict the completion outcome and termination type (if applicable).